A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Clinical trial NCT06492005 · RECRUITING

Trial details

NCT number: NCT06492005
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Triple-Negative Breast Cancer

Start date: 2024-07-26
Primary completion: 2026-07-01
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.